Aurobindo Pharma: Growth Potential Analyzed
Motilal Oswal Financial Services (MOFSL) is optimistic about Aurobindo Pharma (ARBP) and predicts a significant increase in its stock value. They believe the company is poised for strong growth over the next few years. Their analysis shows a potential rise of 18% in the stock price.
Key Points
- Strong Growth Forecasts: Aurobindo Pharma projected to grow 9% in sales, 14% in earnings, and 21% in profit over 3 years.
- Key Markets Drive Growth: US and Europe sales expected to rise significantly (9% and 14% respectively).
- Improved Efficiency: Margin expansion of 90 basis points and lower debt support profitability.
- Valuation Target: MOFSL values the stock at ₹1,430 (12-month forward earnings).
- Strategic Moves: Pen-G expansion, PLI scheme support, and MSD CMO partnership contribute to growth.
- Biosimilars Key: Late-stage pipeline and approvals drive long-term expansion and revenue.
Aurobindo Pharma is focusing on key areas like Pen-G/6-APA expansion, backed by government support through the Production Linked Incentive (PLI) scheme. This helps India become more self-sufficient in producing important medicines.
The brokerage also considers the Minimum Import Price (MIP) policy, if implemented, as a positive factor, encouraging “Make in India” and reducing reliance on imports, especially from China. This policy would further bolster the government’s initiatives.
Biosimilars are seen as a major growth driver. MOFSL highlights CuraTeQ’s pipeline and approvals, along with EU GMP-certified manufacturing, as key to the company’s future success.
Beyond these main strategies, the company is also expanding its injectable medicine pipeline and integrating Lannett, providing additional growth opportunities and driving revenue, earnings, and profit growth over the next three years.
“Investing in Aurobindo Pharma is betting on a diversified approach to growth and a commitment to innovation.”
